Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Poignard

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Immunologic Research|June 14, 2000
Antibodies in human infectious diseaseP W Parren, P Poignard, H J Ditzel, et al.
Journal of Virology|November 17, 2001
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodiesM B Zwick, M Wang, P Poignard, et al.
Immunology Letters|April 15, 1999
Antibody neutralization of HIV-1 and the potential for vaccine designQ J Sattentau, M Moulard, B Brivet, et al.
Immunology Letters|June 1, 1997
Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine designP W Parren, M C Gauduin, R A Koup, et al.
Immunology Letters|July 1, 1997
Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design"P W Parren, M C Gauduin, R A Koup, et al.
Journal of Virology|June 10, 2011
Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivityB K Chakrabarti, L M Walker, J F Guenaga, et al.
Journal of Virology|March 12, 1999
Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccinesH Sakurai, R A Williamson, J E Crowe, et al.
Journal of Virology|April 10, 1999
Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variantsD E Mosier, G R Picchio, R J Gulizia, et al.
Immunity|May 6, 1999
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivoP Poignard, R Sabbe, G R Picchio, et al.
Journal of Virology|September 19, 2014
Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodiesM Bouvin-Pley, M Morgand, L Meyer, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Immunologic Research|June 14, 2000
Antibodies in human infectious diseaseP W Parren, P Poignard, H J Ditzel, et al.
Journal of Virology|November 17, 2001
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodiesM B Zwick, M Wang, P Poignard, et al.
Immunology Letters|April 15, 1999
Antibody neutralization of HIV-1 and the potential for vaccine designQ J Sattentau, M Moulard, B Brivet, et al.
Immunology Letters|June 1, 1997
Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine designP W Parren, M C Gauduin, R A Koup, et al.
Immunology Letters|July 1, 1997
Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design"P W Parren, M C Gauduin, R A Koup, et al.
Journal of Virology|June 10, 2011
Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivityB K Chakrabarti, L M Walker, J F Guenaga, et al.
Journal of Virology|March 12, 1999
Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccinesH Sakurai, R A Williamson, J E Crowe, et al.
Journal of Virology|April 10, 1999
Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variantsD E Mosier, G R Picchio, R J Gulizia, et al.
Immunity|May 6, 1999
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivoP Poignard, R Sabbe, G R Picchio, et al.
Journal of Virology|September 19, 2014
Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodiesM Bouvin-Pley, M Morgand, L Meyer, et al.
Pageof 2